We invite you to join a select group of clinicians who will have early access to the PredicineCARE™ ultra-sensitive comprehensive genomic profile test designed to address unmet clinical needs for patients with advanced stage cancer.
The PredicineCARE Early Access Program is scheduled for October 2021 through January 2022. During this time, Oncologists who participate in the Early Access Program will have the following experience:
Please complete the information below to find out more information.
“Liquid biopsy is the future of precision medicine. Our work with Predicine’s liquid biopsy platform is very encouraging for the field of liquid biopsy and supports its clinical application for patient care.”